GUANGZHOU, China, September 10, 2026 — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today reported unaudited financial results for the three months ended June 30, 2026.

In the second quarter of 2026, the Company generated total revenue of RMB134.7 million (US$19.9 million), representing a 9.3% decrease year-over-year and a 24.8% increase quarter-on-quarter. Revenue generated from in-hospital business was RMB67.1 million (US$9.9 million), representing a 7.4% increase year-over-year and a 27.3% increase quarter-on-quarter. As of June 30, 2026, the Company’s cash, cash equivalents and restricted cash were RMB419.1 million (US$61.8 million).

“After navigating a challenging first quarter, we delivered the anticipated sequential recovery in the second quarter, offsetting the order volatility in the first quarter” said Mr. Yusheng Han, Chairman and Chief Executive Officer of Burning Rock. “With several products having entered the Priority Review Channel and Special Review Procedure for Innovative Medical Devices of CMDE and new registration certificates expected in the coming quarters, we are confident that we will achieve sustainable and meaningful top‑line growth over the long term.”

I. Advancing Regulatory Development of Innovative Products and Growing In-Hospital Testing Business

Driven by supportive policies and continued industry standardization, the Company continues to advance the registration of innovative products and expand its in-hospital testing business. To date, the Company has supported 94 hospitals in establishing standardized in-house NGS testing platforms.

Burning Rock’s WES-based tumor-informed personalized MRD technology platform is the only platform of its kind in China with products having entered the NMPA’s Special Review Procedure for Innovative Medical Devices. To date, two WES-based tumor-informed personalized MRD kits based on the platform have entered the procedure, covering lung and esophageal cancers and focusing on recurrence monitoring and perioperative precision assessment, respectively.

• On August 25, 2026, CanCatch Custom Kit entered the NMPA’s Special Review Procedure for Innovative Medical Devices, becoming the first WES-based tumor-informed personalized MRD kit in China to enter the procedure.
• On September 9, 2026, CanCatch Custom Kit (cPAS) entered the NMPA’s Special Review Procedure for Innovative Medical Devices, becoming the second WES-based tumor-informed personalized MRD kit in China to enter the procedure.

✅ In the second quarter of 2026, the Company generated total revenue of RMB134.7 million (US$19.9 million), representing a 9.3% decrease year-over-year and a 24.8% increase quarter-on-quarter. Revenue generated from in-hospital business was RMB67.1 million (US$9.9 million), representing a 7.4% increase year-over-year and a 27.3% increase quarter-on-quarter.

II. Expanding Global Commercialization and Partnerships

Leveraging its CAP-accredited and CLIA-certified laboratories in China and the United States, established product portfolio and project experience, the Company continues to expand its global commercialization and international partnerships. To date, the Company has collaborated with more than 150 pharmaceutical companies and advanced more than 15 diagnostic development programs, with related products approved in major markets including China, the United States, Europe and Japan.

✅ In the second quarter of 2026, the Company generated revenue of RMB30.8 million (US$4.6 million) from pharma research and development services, representing a 31.8% decrease year-over-year and a 35.5% increase quarter-on-quarter.

✅ In July 2026, the Company entered into a global technology licensing collaboration with Myriad Genetics, Inc. (NASDAQ: MYGN) to further expand the companies’ collaboration in homologous recombination deficiency (“HRD”) testing. The collaboration includes further development of myChoice HRD Plus and the development of a next-generation HRD testing kit incorporating the newly licensed technology into Burning Rock’s proprietary OncoScreen Plus platform, with commercialization expanding from China to multiple global markets.

✅ In the second quarter of 2026, the Company completed 16 external quality assessment (“EQA”) programs. To date, the Company has completed 347 EQA programs organized by recognized institutions in China and internationally, supporting testing accuracy and reporting consistency.

III. Advancing Precision Diagnostics to Support Innovative Oncology Therapies

The Company continues to participate in clinical research to support the development and application of innovative oncology therapies.

✅ In June 2026, a single-arm, open-label Phase II clinical study (NEOTIDE/CTONG2104), conducted by the teams of Professors Yi-Long Wu and Wenzhao Zhong of Guangdong Provincial People’s Hospital in collaboration with Burning Rock, was published in eClinicalMedicine. The study evaluated neoadjuvant sintilimab plus carboplatin and nab-paclitaxel in patients with resectable stage II–IIIB EGFR-mutant non-small cell lung cancer. CanCatch Custom Kit supported molecular profiling, treatment response monitoring and biomarker analysis in the study.

✅ In July 2026, results from ASCEND-Hep (NCT04835675), a prospective, multicenter clinical study conducted by hepatobiliary surgery centers from seven tertiary hospitals in China in collaboration with Burning Rock, were published in BMC Medicine. The study developed a multi-omics early detection model (“MOED”) combining cfDNA methylation and AFP as a non-invasive complementary approach for screening populations at high risk of liver cancer. Burning Rock’s proprietary ELSA-seq technology and OncoCompass® Target supported methylation and gene mutation testing, with all testing performed in CAP-accredited and CLIA-certified laboratories.

IV. Improving Operating Efficiency and Maintaining a Stable Cash Position

✅ In the second quarter of 2026, the Company recorded operating expenses of RMB115.8 million (US$17.1 million), representing a 3.2% decrease from RMB119.6 million for the same period in 2025 and a 19.6% increase quarter-on-quarter.

In the first half of 2026, the Company’s annualized inventory turnover was 2.77 times per year, compared with 2.47 times per year for the full year of 2025, reflecting improved inventory management and working capital efficiency.

✅ As of June 30, 2026, the Company’s cash, cash equivalents and restricted cash were RMB419.1 million (US$61.8 million). The Company’s cash reserves provide support for continued product registration and the global expansion of pharmaceutical partnerships.